Up-regulation of p53 by antisense expression of HPV18 E6 oncogene does not influence the level of MN/CAIX tumor-associated protein in HeLa cervical carcinoma cells

International Journal of Oncology

Volumn 13, Issue 5, 1998, Pages 1081-1086

  Lieskovská, Jaroslava ^a   Kaluzová, Milota ^a   Opavsky, René ^a   Kaluz, Stefan ^a   Pastorek, Jaromír ^a   Kettmann, Richard ^b   Pastoreková, Silvia ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

E6 oncoprotein; HeLa cells; Human papillomaviruses; MN CA IX protein; p53

Indexed keywords

ONCOPROTEIN; PROTEIN P53; TUMOR PROTEIN;

ARTICLE; CARCINOGENESIS; DNA DETERMINATION; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; WART VIRUS;

DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENE PROTEINS, VIRAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 0031760166     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.5.1081     Document Type: Article

References (43)

1. Zur Hausen H: Viruses in human cancers. Science 254: 1167-1173, 1991.
2. Zur Hausen H: Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288: F55-F78, 1996.
3. Mansur CP and Androphy EJ: Cellular transformation by papillomavirus oncoproteins. Biochim Biophys Acta 1155: 323-345, 1993.
4. Münger K, Phelps WC, Bubb V, Howley PM and Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63: 4417-4421, 1989.
5. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR and Schiller JT: HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8: 3905-3910, 1989.
6. Von Knebel-Doeberitz M, Oltersdorf T, Schwarz E and Gissmann L: Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-I cervical carcinoma cells. Cancer Res 48: 3780-3786, 1988.
7. Barbosa MS, Lowy DR and Schiller JT: Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol 63: 1404-1407, 1989.
8. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
9. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
10. Hoppe-Seyler F and Butz K: Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol 67:3111-3117, 1993.
11. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH and Laimins LA: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBOJ 11:3045-3052, 1992.
12. Donehower LA and Bradley A: The tumor suppressor p53. Biochem Biophys Acta 1155: 181-205, 1993.
13. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
14. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
15. Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ and Shenk T: Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 89: 12028-12032, 1992.
16. Truant R, Xiao H, Ingles J and Greenblatt J: Direct interaction between transcription activation domain of human p53 and the TATA box-binding protein. J Biol Chem 268: 2284-2287, 1993.
17. Agoff SN, Hou J, Linzer DIH and Wu B: Regulation of the human hsp 70 promoter by p53. Science 259: 84-87, 1993.
18. Desaintes C, Hallez S, Detremmerie O and Burny A: Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters trough the epithelial specific enhancer. Oncogene 10: 2155-2161, 1995.
19. Hinds PW and Weinberg RA: Tumor suppresor genes. Curr Opin Genet Dev 4: 135-141, 1994.
20. Crook T, Wrede D and Vousden KH: p53 point mutation in HPV negative human carcinoma cell lines. Oncogene 6: 873-875, 1991.
21. Pastorek J, Pastoreková S, Callebaut I, Mornon JP, Zelník V, Opavsky R, Zat'ovicová M, Liao S, Portetelle D, Stanbridge EJ, Závada J, Burny A and Kettmann R: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 9: 2878-2888, 1994.
22. Opavsky R, Pastoreková S, Zelník V, Gibadulinová A, Stanbridge EJ, Závada J, Kettmann R and Pastorek J: Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33: 480-487, 1996.
23. Pastoreková S, Závadová Z, Kost'ál M, Babusíková O and Zdvada J: A novel quasi-viral agent MaTu, is a two-component system. Virology 187: 620-626, 1992.
24. Závada J, Závadová Z, Pastoreková S, Ciampor F, Pastorek J and Zelník V: Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54: 268-274, 1993.
25. Liao SY, Brewer C, Závada J, Pastorek J, Pastoreková S, Manetta A, Berman M, DiSaia PJ and Stanbridge EJ: Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145: 598-609, 1994.
26. McKieman JM, Buttyan R, Bander NH, Stifelman MD, Katz AE, Chen MW, Olsson CA and Sawczuk IS: Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 57: 2362-2365, 1997.
27. Uemura H, Kitagawa H, Hirao Y and Okajima E: Expression of tumor-associated antigen MN/G250 in urologie carcinoma: potential therapeutic target. J Urol 157S: 377, 1997.
28. Turner JR, Odze RD, Crum CP and Resnick MB: MN antigen expression in normal, prencoplastic, and neoplastic esophagus: A clinicopathological study of a new cancer-associated biomarker. Hum Pathol 28: 740-744, 1997.
29. Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastoreková S, Pastorek J, Kairaluoma MI and Karttunen TJ: Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153: 279-285, 1998.
30. Liao SY and Stanbridge EJ: Expression of the MN antigen in cervical Papanicolaou smears is an early diagnostic biomarker of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 5: 549-557, 1996.
31. Gossen M and Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992.
32. Niewolik D, Vojtesek B and Kovarik J: p53 derived from human tumor cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10: 881-890, 1995.
33. Willems L, Kettmann R, Chen G, Portetelle D, Burny A and Derse D: A cyclic AMP-responsive DNA-binding protein (CREB2) is a cellular transactivator of the bovine leukemia virus long terminal repeat. J Virol 66: 766-772, 1992.
34. Vojtesek B, Martek J, Midgley CA and Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244, 1992.
35. Pecoraro G, Morgan D and Defendi V: Differential effect of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 86: 563-567, 1989.
36. Zheng J, Wahlstrom T, Paavonen J and Vaheri A: Altered growth behaviour of human cervical epithelial cells transfected by HPV type 16 and 18 DNA. Int J Cancer 58: 713-720, 1994.
37. Pecoraro G, Lee M, Morgan D and Defendi V: Evolution of in vitro transformation and tumorigenesis of HPV16 and HPV18 immortalized primary cervical epithelial cells. Am J Pathol 138: 1-8, 1990.
38. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871, 1992.
39. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1: 45-49, 1992.
40. Benchimol S, Pim D and Crawford L: Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J 1: 1055-1062, 1982.
41. Butz K, Geisen C, Ullmann A, Spitkovsky D and Hoppe-Seyler F: Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 68: 506-513, 1996.
42. Resnick M, Lester S, Tate JE, Sheets EE, Sparks C and Crum CP: Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia. Hum Pathol 27: 234-239, 1996.
43. Brewer CA, Liao SY, Wilczynski SP, Pastoreková S, Pastorek J, Závada J, Kurosaki T, Manetta A, Berman ML, Di Saia PJ and Stanbridge EJ: A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol 63: 337-344, 1996.